hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06387498, orgStudyIdInfo id: 20-2286, briefTitle: Testicular Tissue Cryopreservation (TTC), acronym: TTC, statusModule overallStatus: RECRUITING, startDateStruct date: 2020-09-28, primaryCompletionDateStruct date: 2027-12-30, completionDateStruct date: 2027-12-30, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: University of Colorado, Denver, class: OTHER, descriptionModule briefSummary: The "Testicular Tissue Cryopreservation" study is open to a subset of patients facing disease or treatment regimens that could lead to infertility (gonadotoxic therapies). For some of these patients, experimental testicular tissue cryopreservation is the only fertility preservation option available. The overall objective of this study is to determine the feasibility and acceptability of testicular tissue cryopreservation in male patients of all ages who have a condition or will undergo a treatment that can cause infertility., conditionsModule conditions: Fertility Issues, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Testicular tissue biopsy and cryopreservation, outcomesModule primaryOutcomes measure: Feasibility, as Assessed via the Percentage of Eligible Patients who do a Procedure, primaryOutcomes measure: Feasibility, as Assessed via Percentage of Patients who Attempted a Procedure who were able to Cryopreserve, primaryOutcomes measure: Safety, as Assessed via the Number of Participants with At Least One Pre-specified Adverse Event, primaryOutcomes measure: Safety, as Assessed via the Number of Participants with At Least One Pre-specified Adverse Event, primaryOutcomes measure: Safety, as Assessed via the Number of Participants with At Least One Pre-specified, primaryOutcomes measure: Safety, as Assessed via the Number of Participants with At Least One Pre-specified, secondaryOutcomes measure: Acceptability, as Assessed via Annual Survey Regret Score, eligibilityModule sex: MALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Colorado, status: RECRUITING, city: Aurora, state: Colorado, zip: 80045, country: United States, contacts name: Jocelyn Phipers, RN, role: CONTACT, phone: 303-724-7807, email: jocelyn.phipers@cuanschutz.edu, contacts name: Leslie Appiah, MD, role: CONTACT, email: LESLIE.APPIAH@CUANSCHUTZ.EDU, contacts name: Leslie Appiah, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.72943, lon: -104.83192, hasResults: False
protocolSection identificationModule nctId: NCT06387485, orgStudyIdInfo id: SR-001, briefTitle: A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-04-01, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Ricoh USA, Inc., class: INDUSTRY, descriptionModule briefSummary: This prospective, multi-center, randomized controlled study aims to assess the efficacy of utilizing 3D printed models in preoperative planning for the excision of tumors involving bony structures within the body. The study is expected to last approximately 12 months and involve up to 150 subjects across 3 sites. Subjects will be randomized in a 1:1 ratio into either the experimental arm, utilizing 3D printed models and imaging, or the active comparator arm, using only imaging.Primary endpoint: Operative time of surgical procedure.Secondary endpoints: Reduction of blood loss, proportion of postoperative adverse events, and negative tumor margins.Exploratory endpoints: Surgical planning ease, changes in surgical plan, and surgeon satisfaction., conditionsModule conditions: Sarcoma, Ewing, conditions: Chondrosarcoma, conditions: Osteosarcoma, conditions: Fibrous Histiocytoma, conditions: Fibrosarcoma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: 3D Printed Anatomic Model, interventions name: CT/MRI, outcomesModule primaryOutcomes measure: Operative time, secondaryOutcomes measure: Blood loss, secondaryOutcomes measure: Adverse Events, secondaryOutcomes measure: Tumor margin status, eligibilityModule sex: ALL, minimumAge: 22 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: William Beaumont University Hospital, status: RECRUITING, city: Royal Oak, state: Michigan, zip: 48073, country: United States, contacts name: Pamela Sloan, RN, CCRP, role: CONTACT, phone: 248-551-6059, email: Pamela.Sloan@corewellheath.org, geoPoint lat: 42.48948, lon: -83.14465, locations facility: The Ohio State University Wexner Medical Center, status: RECRUITING, city: Columbus, state: Ohio, zip: 43212, country: United States, contacts name: Rachel Herster, BS, role: CONTACT, phone: 248-514-4490, email: rachel.herster@osumc.edu, geoPoint lat: 39.96118, lon: -82.99879, hasResults: False
protocolSection identificationModule nctId: NCT06387472, orgStudyIdInfo id: 23-007636, briefTitle: DermAI to Evaluate Human Factor of Testing, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-29, primaryCompletionDateStruct date: 2024-08-01, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: The purpose of this research is to improve how well remote patch allergy testing works and make sure they are easy and practical for people to use from home., conditionsModule conditions: Contact Dermatitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: AI algorithm to evaluate photographs of skin test patch regions, interventions name: Allergen Patch, outcomesModule primaryOutcomes measure: Classification of test site region reaction, secondaryOutcomes measure: Classification of test site region using a 5-point scale, secondaryOutcomes measure: False Positive Rate, secondaryOutcomes measure: False Negative Rate, secondaryOutcomes measure: Early termination of testing, secondaryOutcomes measure: Participants that removed patches early, secondaryOutcomes measure: Adverse events related to allergen exposure, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Florida, status: RECRUITING, city: Jacksonville, state: Florida, zip: 32224, country: United States, contacts name: Laura Pacheco-Spann, role: CONTACT, phone: 904-953-0408, email: FLAQHSCS@mayo.edu, contacts name: Matthew Hall, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.33218, lon: -81.65565, hasResults: False
protocolSection identificationModule nctId: NCT06387459, orgStudyIdInfo id: 2022M3C1A3090827, briefTitle: Feasibility of Fabric Orthosis for Knee Support in Elderly Gait Improvement, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-15, primaryCompletionDateStruct date: 2025-05-14, completionDateStruct date: 2026-05-14, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Seoul National University Hospital, class: OTHER, collaborators name: Ministry of Science and ICT, descriptionModule briefSummary: This pilot clinical trial assesses the safety and feasibility of a novel fabric-type orthosis designed to mimic the knee extensor muscles and improve gait in elderly patients with mobility impairments due to conditions like sarcopenia, diabetes, or knee osteoarthritis. The study aims to test this orthosis in a real- world setting to see if it can enhance mobility and stability for elderly individuals, potentially reducing falls and improving quality of life. A total of 30 participants aged 65 and older will be recruited to use this orthosis across multiple sessions, where their gait will be analyzed under various conditions to measure the device's impact on walking speed, stability, and muscle activation., conditionsModule conditions: Gait, conditions: Fall, conditions: Orthotic Devices, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Fabric-Type Knee Extensor Muscle-Mimicking Orthosis, outcomesModule primaryOutcomes measure: Completion Rate, secondaryOutcomes measure: Dropout Rate, secondaryOutcomes measure: User Feedback, secondaryOutcomes measure: 6-Minute Walk Test, secondaryOutcomes measure: 10-Meter Walk Test, secondaryOutcomes measure: Surface Electromyography, secondaryOutcomes measure: Gait Analysis, eligibilityModule sex: ALL, minimumAge: 65 Years, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06387446, orgStudyIdInfo id: RB-P00044611, briefTitle: Allogeneic Valve Transplantation, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2027-06-01, completionDateStruct date: 2027-06-01, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Boston Children's Hospital, class: OTHER, descriptionModule briefSummary: Valves will be taken from hearts donated by organ donors, and implanted into patients who need a new heart valve., conditionsModule conditions: Valve Heart Disease, conditions: Valve Disease, Heart, conditions: Valve Disease, Aortic, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 4, type: ESTIMATED, armsInterventionsModule interventions name: Valve transplant, outcomesModule primaryOutcomes measure: Valve Regurgitation, primaryOutcomes measure: Valve Annulus Growth, primaryOutcomes measure: Leaflet Growth, secondaryOutcomes measure: Ventricular Function, secondaryOutcomes measure: Survival, eligibilityModule sex: ALL, minimumAge: 30 Days, maximumAge: 50 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Boston Children's Hospital, status: RECRUITING, city: Boston, state: Massachusetts, zip: 02115, country: United States, contacts name: Sitaram Emani, MD, role: CONTACT, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06387433, orgStudyIdInfo id: mHealth, secondaryIdInfos id: SG-222/R3-05/RDC/DUHS/1478, type: OTHER_GRANT, domain: National Institutes of Health Pakistan, briefTitle: Effectiveness of an mHealth Mobile App, acronym: mHealth, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2025-08, completionDateStruct date: 2025-08, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Dow University of Health Sciences, class: OTHER, collaborators name: National Institutes of Health (NIH), descriptionModule briefSummary: Type II diabetes is a serious challenge for Pakistan. Not using medications properly increases healthcare costs and diabetes-related deaths. A mobile app in local language can improve medication adherence and self-management among diabetics. Therefore, in this 18 months long study we will develop a diabetes-related mobile application in Urdu, and will conduct a trial to assess whether it improves medication compliance and self-management, and how much economical this app would be compared to the usual standard of care for type II diabetics in Pakistan. This trial will be conducted at the National Institute of Diabetes and Endocrinology Karachi. The study participants will be divided in two groups. Only one group will use this application. We will measure medication compliance and self-management through diabetes-specific blood test and self-reporting questionnaires between two groups. We will also determine how much economic costs would be saved by using this app to improve medication compliance, conditionsModule conditions: Type II Diabetes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 160, type: ESTIMATED, armsInterventionsModule interventions name: mobile app use, outcomesModule primaryOutcomes measure: adherence to medication, primaryOutcomes measure: self-management among diabetics, secondaryOutcomes measure: Intervention usability, secondaryOutcomes measure: economic effectiveness of the app, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Institute of Diabetes and Endocrinology, city: Karachi, state: Sindh, country: Pakistan, geoPoint lat: 24.8608, lon: 67.0104, hasResults: False
protocolSection identificationModule nctId: NCT06387420, orgStudyIdInfo id: AK117-206, briefTitle: A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-29, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2027-04, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Akeso, class: INDUSTRY, descriptionModule briefSummary: This is a phase 1b/2 study. All patients are diagnosed with Acute Myeloid Leukemia (AML), Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine + venetoclax in subjects with AML., conditionsModule conditions: ACUTE MYELOID LEUKEMIA; AML, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 180, type: ESTIMATED, armsInterventionsModule interventions name: AK117, interventions name: Azacitidine, interventions name: Venetoclax, interventions name: Placebo, outcomesModule primaryOutcomes measure: Phase 1b: Number of participants with dose limiting toxicity (DLT), primaryOutcomes measure: Phase 1b/2: Number of participants with adverse events (AEs), primaryOutcomes measure: Phase 1b/2: Composite complete remission rate (CCR), secondaryOutcomes measure: Overall response rate (ORR), secondaryOutcomes measure: Time to response (TTR), secondaryOutcomes measure: Time to CCR (TTCCR), secondaryOutcomes measure: Duration of response (DoR), secondaryOutcomes measure: Duration of CCR (DoCCR), secondaryOutcomes measure: Rate of CCR Without Minimal Residual Disease (CCR MRD-), secondaryOutcomes measure: Event-free survival (EFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Peak of Serum Concentration (Cmax), secondaryOutcomes measure: Anti-drug antibody (ADA), secondaryOutcomes measure: Receptor occupancy (RO), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, city: Tianjin, country: China, contacts name: Jianxiang Wang, role: CONTACT, geoPoint lat: 39.14222, lon: 117.17667, hasResults: False
protocolSection identificationModule nctId: NCT06387407, orgStudyIdInfo id: 2024037K, briefTitle: Population Pharmacokinetic Study of the Effect of Polymorphisms in the ABCB1 and CES1 Genes on the Pharmacokinetics of Dabigatran, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-06-10, completionDateStruct date: 2025-11-25, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: The Affiliated Hospital Of Guizhou Medical University, class: OTHER, descriptionModule briefSummary: According to published studies, the effects of genetic polymorphisms in the ABCB1 and CES1 genes on the blood concentration of dabigatran are controversial, and it is not clear whether dabigatran dosage and dosing intervals need to be adjusted according to genotype or other covariates in Chinese subjects. For these purposes, we will include patient demographics, genetic polymorphisms, and PK data based on a population pharmacokinetic study of dabigatran ester in healthy Chinese subjects to analyze the effect on dabigatran pharmacokinetics.The aim of this study was to develop a population pharmacokinetic model to understand the relationship between dabigatran-related genes and dabigatran plasma levels after a single oral dose in healthy Chinese subjects and patients, and to analyze the effects of genetic variation on the efficacy and safety of dabigatran etexilate., conditionsModule conditions: Combined Analysis of Polymorphisms and Dabigatran Pharmacokinetic Parameters, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Dabigatran Etexilate 150mg, outcomesModule primaryOutcomes measure: Plasma drug concentration, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 89 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06387381, orgStudyIdInfo id: CYYY-KY-2024-048-01, briefTitle: 68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-04-30, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: First Affiliated Hospital of Chongqing Medical University, class: OTHER, descriptionModule briefSummary: As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA/FAP positive diseases., conditionsModule conditions: PSMA, conditions: FAP, conditions: Positron-Emission Tomography, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: 68Ga-PSFA, outcomesModule primaryOutcomes measure: Diagnostic efficacy, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Chongqing Medical University, status: RECRUITING, city: Chongqing, state: Chongqing, zip: 400016, country: China, contacts name: Xiaoyang Zhang, PhD, role: CONTACT, phone: 023-89011755, email: zhangxy@mail.bnu.edu.cn, geoPoint lat: 29.56278, lon: 106.55278, hasResults: False
protocolSection identificationModule nctId: NCT06387368, orgStudyIdInfo id: HE-202303, briefTitle: Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2028-03, completionDateStruct date: 2028-08, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Health Science Center of Xi'an Jiaotong University, class: OTHER, collaborators name: LinkDoc Technology (Beijing) Co. Ltd., collaborators name: Huazhong University of Science and Technology, descriptionModule briefSummary: This is a prospective, multicenter, randomized, open, parallel controlled clinical study to evaluate the efficacy and safety of Huaier Granules combined with capecitabine in the treatment of unresectable pancreatic cancer., conditionsModule conditions: Pancreatic Cancer Non-resectable, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 488, type: ESTIMATED, armsInterventionsModule interventions name: Huaier Granule, interventions name: Capecitabine, outcomesModule primaryOutcomes measure: Overall survival, secondaryOutcomes measure: Objective response rate, secondaryOutcomes measure: Progression free survival, secondaryOutcomes measure: Conversion surgery rate, secondaryOutcomes measure: The incidence and severity of adverse events (AE) and severe adverse events (SAE), secondaryOutcomes measure: The incidence and severity of ADR, severe adverse reactions (SADR), suspicious and unexpected severe adverse reactions (SUSAR), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False